Sentences with phrase «refractory solid tumors»

A phase I trial of ramucirumab, a human monoclonal antibody against the vascular endothelial growth factor - 2 (VEGFR - 2) receptor, in children with refractory solid tumors, including CNS tumors (NCT02564198).

The Phase 1 open - label, multicenter, dose escalation study of mRNA - 2416 is designed to determine the safety and tolerability of escalating iTu doses of mRNA - 2416 in patients with relapsed / refractory solid tumor malignancies or lymphoma, and define the maximum tolerated dose (MTD) and recommended dose for expansion (RDE) and schedule for iTu injections of mRNA - 2416.

The multikinase angiogenesis inhibitor pazopanib was well tolerated and exhibited some responses in pediatric patients with soft - tissue sarcomas and other refractory solid tumors in a phase I trial.

Pharmacokinetics of 5 - azacytidine given with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies.

This is a two - part Phase I - II, nonrandomized, open - label, single - arm, multi-center trial to evaluate the pharmacokinetics (PK), pharmacodynamics, toxicity, safety, and anti - tumor activity of MK - 3475 (also known as pembrolizumab) in pediatric subjects aged 6 months to less than 18 years of age with either advanced melanoma or a PD - L1 positive advanced, relapsed or refractory solid tumor or lymphoma.

A Phase I / II Study of Pembrolizumab (MK - 3475) in Children with Advanced Melanoma or a PD - L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma

A Phase 1, Open - Label, Dose - Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine / Irinotecan, or High - Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors

A phase I trial of ramucirumab, a human monoclonal antibody against the vascular endothelial growth factor - 2 (VEGFR - 2) receptor, in children with refractory solid tumors, including CNS tumors -LRB-